Current	JJ
and	CC
novel	JJ
drug	NN
therapies	NNS
for	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
.	.

Over	IN
the	DT
past	JJ
decade	NN
,	,
there	EX
has	VBZ
been	VBN
a	DT
cohesive	JJ
effort	NN
from	IN
patients	NNS
,	,
physicians	NNS
,	,
clinical	JJ
and	CC
basic	JJ
scientists	NNS
,	,
and	CC
the	DT
pharmaceutical	JJ
industry	NN
to	TO
find	VB
definitive	JJ
treatments	NNS
for	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

As	IN
understanding	NN
of	IN
disease	NN
behavior	NN
and	CC
pathogenesis	NN
has	VBZ
improved	VBN
,	,
the	DT
aims	NNS
of	IN
those	DT
treating	VBG
IPF	NN
have	VBP
shifted	VBN
from	IN
reversing	VBG
the	DT
disease	NN
to	TO
slowing	VBG
or	CC
preventing	VBG
progression	NN
of	IN
this	DT
chronic	JJ
fibrotic	JJ
illness	NN
.	.

It	PRP
is	VBZ
to	TO
be	VB
hoped	VBN
that	IN
by	IN
slowing	VBG
disease	NN
progression	NN
,	,
survival	NN
will	MD
be	VB
improved	VBN
from	IN
the	DT
current	JJ
dismal	JJ
median	NN
of	IN
3.5	CD
years	NNS
following	VBG
diagnosis	NN
.	.

In	IN
Europe	NNP
and	CC
Asia	NNP
,	,
a	DT
milestone	NN
has	VBZ
recently	RB
been	VBN
reached	VBN
with	IN
the	DT
licensing	NN
of	IN
the	DT
first	JJ
IPF-specific	JJ
drug	NN
,	,
pirfenidone	NN
.	.

This	DT
review	NN
assesses	VBZ
the	DT
current	JJ
treatment	NN
modalities	NNS
available	JJ
for	IN
IPF	NN
,	,
including	VBG
pirfenidone	NN
.	.

It	PRP
also	RB
turns	VBZ
an	DT
eye	NN
to	TO
the	DT
future	NN
and	CC
discusses	VBZ
the	DT
growing	VBG
number	NN
of	IN
promising	JJ
compounds	NNS
currently	RB
in	IN
development	NN
that	IN
it	PRP
is	VBZ
hoped	VBN
,	,
in	IN
time	NN
,	,
will	MD
make	VB
their	PRP$
way	NN
into	IN
the	DT
clinic	NN
as	IN
treatments	NNS
for	IN
IPF	NN
.	.

